OV90 CDX Model

The OV90 cell line is derived from human ovarian cancer, a malignancy known for its late-stage diagnosis and associated challenges in treatment. Ovarian cancer has various subtypes, each with unique molecular signatures and clinical manifestations. The OV90 cell line offers an invaluable platform for delving into the intricate biology, progression, and therapeutic nuances associated with ovarian cancer. Encompassing key molecular characteristics and genetic mutations emblematic of ovarian cancer patients, OV90 is a significant asset in preclinical research. The behavior of OV90, both in vitro and in vivo, provides crucial insights into the growth dynamics, metastatic tendencies, and drug sensitivities or resistances typical of ovarian tumors. Researchers frequently use the OV90 model to understand the molecular underpinnings of ovarian cancer, to evaluate the potency of new therapeutic agents, and to investigate potential resistance mechanisms to frontline treatments.

Model Details

Cancer Location: Ovarian
Cancer Type: Ovarian Cancer
Model Name: OV90
Mouse Strain: NSG
Treatment Data Available: Chemotherapy (Paclitaxel, Cisplatin, Nirprib)

A2780/CP Growth curves

OV90 CDX Model

Growth of subcutaneous A2780 in Nu/Nu mice (n=5)

Request Additional CDX Model Data


Get Started.

Have questions about how TD2 can assist with your regulatory needs? Reach out to our expert staff today to get started.